Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/104853
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer |
Author: | Muralidhar, V. Catalano, P. Reznor, G. Mahal, B. Choueiri, T. Sweeney, C. Martin, N. Beard, C. Chen, Y. Nezolosky, M. Hoffman, K. Feng, F. Trinh, Q. Nguyen, P. |
Citation: | Journal of the National Comprehensive Cancer Network : JNCCN, 2016; 14(4):421-428 |
Publisher: | Jones and Barlett Publishers |
Issue Date: | 2016 |
ISSN: | 1540-1405 1540-1413 |
Statement of Responsibility: | Vinayak Muralidhar, Brandon Arvin Virgil Mahal, Gally Reznor, Toni K. Choueiri, Christopher Sweeney, Neil E. Martin, Peter F. Orio, Yu-Wei Chen, Michelle Daniel Nezolosky, Karen E. Hoffman, Felix Yi-Chung Feng, Quoc-Dien Trinh, Paul L. Nguyen |
Abstract: | The current NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer recommend long-term androgen deprivation therapy (ADT) for all men with high-risk prostate cancer treated with external-beam radiation therapy (EBRT). We determined whether the use of long-term ADT varied by the recently defined subcategories of high-risk disease (favorable, other, and very high) versus unfavorable intermediate-risk disease.We identified 5,524 patients with unfavorable-risk prostate cancer diagnosed from 2004 to 2007 and managed with EBRT using the SEER-Medicare linked database. Patients were stratified by risk group: unfavorable intermediate-risk, favorable high-risk (previously defined and validated as clinical stage T1c, Gleason score of 4 + 4 = 8, and prostate-specific antigen [PSA] level <10 ng/mL, or clinical stage T1c, Gleason score of 6, and PSA level >20 ng/mL), very-high-risk (clinical stage T3b-T4 or primary Gleason pattern 5), or other high risk (ie, neither favorable nor very high). We used multivariable competing risks regression to estimate the rates of long-term (≥2 years) ADT by group.Men with favorable high-risk prostate cancer were significantly less likely to receive long-term ADT than those with other high-risk disease (15.4% vs 24.6%, adjusted hazard ratio [AHR], 0.68; 95% CI, 0.60-0.76;P<.001), and similarly likely as those with unfavorable intermediate-risk disease (AHR, 1.10; 95% CI, 0.99-1.23;P=.087). Other high-risk disease was less likely to receive long-term ADT than very high-risk cancer (24.6% vs 30.8%; AHR, 0.83; 95% CI, 0.74-0.93;P=.002).Despite current guidelines, patients with EBRT-managed high-risk prostate cancer received significantly different rates of long-course ADT based on subclassification. Our results suggest that oncologists view these patients as a heterogeneous group with favorable high-risk cancer warranting less aggressive therapy than other high-risk or very high-risk disease. |
Keywords: | Androgen deprivation therapy; African-American men; cardiovascular-disease; radiation-therapy; trial; radiotherapy; suppression; mortality; duration |
Rights: | Copyright © 2016 by the National Comprehensive Cancer Network. |
DOI: | 10.6004/jnccn.2016.0048 |
Published version: | http://dx.doi.org/10.6004/jnccn.2016.0048 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.